Overexpression of CYR61 in breast cancer cells caused resistance to paclitaxel and PI3K pathway inhibitors, suggesting activation of the pro-survival PI3K pathway as a mechanism for resistance [59]. Here, CCN1 is linked to breast carcinoma.